Curcumin for monoclonal gammopathies. What can we hope for, what should we fear?

Vermorken, A.J.M.; Zhu, Jingjing; Ven, W.J.M. Van de; Andrès, Emmanuel

doi:10.1016/j.critrevonc.2012.04.005

Cited by 5 publications

(3 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies have identified down-regulation of interleukin-6 (a growth factor for myeloma and also an inflammatory cytokine) and suppression of receptor activator of nuclear factor kappa-B ligand (RANKL) signaling as two possibilities [2][3][4]8] . In their recent review [9] , Vermorken et al have attributed the beneficial effect of curcumin to its potential anti-inflammatory action. They also expressed concerns about the possible immunosuppressive effects of curcumin and its effects on cellular immunity.…”

Section: Discussionmentioning

confidence: 99%

Long term use of curcumin in two smoldering multiple myeloma patients

et al. 2013

View full text Add to dashboard Cite

Introduction: Smoldering Multiple Myeloma (SMM) is an asymptomatic plasma cell disorder which has an overall risk of progression to multiple myeloma of 10% per year. The cornerstone of managing SMM is a "watch and wait" strategy. Curcumin has been shown to improve disease status in some patients with MGUS and SMM and has been added to the mainstream treatment of myeloma patients. We report here for the first time on long term use of oral curcumin in 2 SMM patients.Patients: Two male Caucasian patients over the age of 40 presented to their general practitioners with fatigue/shoulder pain. Blood tests revealed paraproteinemia and a diagnosis of SMM was made based on IMWG guidelines. Both were entered into a 9 month clinical trial of oral curcumin in patients with plasma cell dyscrasias. Thereafter, they elected to continue on the same regimen of oral curcumin, for a period of 2 years. Results/Discussion: Both patients showed continued improvement in a number of markers of disease activity including serum free light chains, paraprotein and % plasma cells in the bone marrow. These results suggest that patients with smoldering myeloma may benefit from daily ingestion of curcumin and long term use does not result in toxicity.

show abstract

Section: Discussionmentioning

confidence: 99%

Long term use of curcumin in two smoldering multiple myeloma patients

et al. 2013

View full text Add to dashboard Cite

show abstract

“…The mean retention rate of RBC as determined by microsphiltration in a subgroup of 18 hyposplenic patients was 9.6% vs. 1.08% in 18 controls, strongly suggesting that hyposplenic patients have on average a greater proportion of poorly deformable RBC than subjects with normal splenic function. Taken together, these observations strengthen the assumption that subtle but measurable mechanical alterations induce the retention of senescent RBC in the spleen [5]. Measuring the elongation index of circulating RBC is physiologically relevant, requires only small volumes of blood, and provides reproducible, operator-independent results [2].…”

Section: Terry Golombickmentioning

confidence: 50%

“…Nevertheless, there are reasons for concern about safety in patients with monoclonal gammopathies [5]. As stated by the authors, curcumin may benefit some but not all patients with high risk MGUS.…”

mentioning

confidence: 90%